NBSE News and Press, NeuBase Therapeutics Inc. From 05/14/20

- - - Announced positive preclinical data that validates the key advantages of the proprietary NeuBase peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform - - - Completed a public offering with net proceeds of approximately $33.3 million in April 2020, strengthen...

6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series Fireside Chat at 2:30 p.m. ET on May 15 TH RBC Capital Markets 2020 Global Healthcare Conference presentation at 1:20 p.m. ET on May 20 TH PITTSBURGH, May 11, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeuti...

PITTSBURGH, April 30, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the closing of its previously announced ...

NeuBase Therapeutics ( NBSE -11.4% ) has priced its public offering of 5.25M common shares at $6/share. More news on: NeuBase Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

PITTSBURGH, April 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the pricing of an underwritten public of...

NeuBase Therapeutics (NASDAQ: NBSE )  -15%  on equity offering . More news on: NeuBase Therapeutics, Inc., Yield10 Bioscience, Inc., Blueprint Medicines Corporation, Stocks on the move, , Read more ...

PITTSBURGH, April 27, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today that it has commenced an underwritten pu...

Demonstrates broad biodistribution, including across the blood-brain barrier into the central nervous system, and into skeletal muscle, in non-human primates (“NHPs”) after systemic administration Durable and therapeutically relevant drug concentrations achieved in NHP...

NeuBase Therapeutics (NASDAQ: NBSE ): Q1 GAAP EPS of -$0.26 beats by $0.06 . More news on: NeuBase Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PITTSBURGH, March 26, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to add...